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Regulation  of B  cell  immune  responses  requires  an  understanding  of the 
cellular and molecular processes that govern such events. The role of T  lympho- 
cytes in B cell development has been recognized for over a decade, but recently 
this concept has matured  to encompass a  battery of antigen-nonspecific  geneti- 
cally unrestricted T  cell-derived factors that regulate B cell function (1-16). We 
have identified one such factor, initially designated B cell growth factor (BCGF),' 
which appears to be required for the proliferation  of a population of splenic B 
cells (13). This factor has recently been renamed BCGF-I to distinguish it from 
a  second  B  cell  proliferation  cofactor,  BCGF-II  (17).  BCGF-I synergizes  with 
anti-IgM antibodies to cause polycional B cell proliferation (13). It appears to act 
on early G1 phase B cells (18) and does not lead to development of Ig-secreting 
cells  in  the  absence  of additional  factors  (13,  16).  It  is  present  in  induced 
supernatants of the cloned murine thymoma EL4 (13) and thus is presumably T 
cell derived. 
To  explore  the  mechanism  of production  of BCGF-I  in  a  normal  antigen- 
driven immune response, we have examined in detail the products of a continu- 
ously growing T  cell line following antigenic stimulation. Antigen-reactive T  cell 
lines  can  be generated  by serial  restimulation  of antigen-primed  T  cells  with 
irradiated  spleen cells plus antigen,  followed by antigen-free periods when the 
cells are maintained on irradiated spleen cells alone (19). Such lines are capable 
of supporting  a  variety  of in  vitro  B  cell  responses,  and  thus  seemed  likely 
candidates for potential  BCGF-producers.  A  T  cell line specific for the protein 
antigen  ovalbumin (OVA) was produced and tested over the course of 18 mo. 
When  the  line  was stimulated  with  OVA in  the context of syngeneic antigen- 
presenting cells (APC), it rapidly produced levels of BCGF-I comparable to those 
in induced EL4 supernatants.  As few as I04 T  cells produced sufficient BCGF-I 
to signficantly enhance proliferation of 5 ×  104 purified anti-Ig activated B cells. 
Antigen-reactive  T  cells produced large amounts of BCGF-I in  the absence of 
presented  antigen  if instead  they were provided with  purified  preparations  of 
interleukin 2 (IL-2). From these and our previously published results, we propose 
I Abbreviations used in this paper: APC, antigen presenting cells; BCGF, B cell growth factor; IEF, 
isoelectric focusing; IL-2, interleukin 2; OVA, ovalbumin; PMA, phorbol myristate acetate. 
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a  model for the cellular and molecular chain of events leading to B cell prolif- 
eration in an antigen-induced immune response. 
Materials and Methods 
Mice.  BALB/c, B10.A, B10.S(9R), and CBA/J mice were obtained from The Jackson 
Laboratory (Bar Harbor, ME). CBA/N mice were obtained from the Division of Research 
Services, National Institutes of Health. All mice were used at 8-12 wk of age. 
Anti-lgM.  Affinity column-purified goat antibody specific for mouse t* heavy chains 
(anti-t*) was prepared as previously described (20). 
Factor Preparations.  EL4 supernatant was obtained by stimulating a cloned subline of 
EL4 thymoma with  10 ng/ml phorbol myristate acetate (PMA) as described elsewhere 
(21). For some experiments, an IL-2-rich, BCGF-I-free component of these supernatants 
was obtained either by isoelectric focusing (IEF) or by phenyl Sepharose chromatography 
according  to  procedures  published  elsewhere  (22,  23).  Purified  human  IL-2  kindly 
provided  by  Dr.  Kendall  A.  Smith  (Dartmouth  Medical  School,  Hanover,  NH)  was 
prepared as follows. IL-2-containing supernatant was obtained from a phytohemagglutin 
(1.5  t*g/ml,  Wellcome Reagents  Limited, Beckenham,  England) and  PMA  (50 ng/ml, 
Consolidated Midland Corp., Brewster, NY) stimulated human leukemic T cell line (Jurkat 
subclone 6.8).  This  supernatant  was  concentrated and  applied  to  an  immunoaffinity 
column constructed with an IgG~a monoclonal antibody to human IL-2. Bound IL-2 was 
eluted with 0.2 N acetic acid. The eluted material appeared to be a single polypeptide, 
15,500 (Mr) when analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and showed a single spot on two-dimensional PAGE. For all preparations of 
IL-2, activity was measured via proliferation of the IL-2-dependent T  cell clone HT2, as 
detailed elsewhere (13). 
Culture Medium.  The culture medium used throughout was RPMI  1640 (Gibco Lab- 
oratories, Grand Island, NY) supplemented with 10% fetal calf serum (Reheis, Kankakee, 
1L), penicillin (50 t*g/ml), streptomycin (50 t*g/ml), gentamicin (100 t*g/ml), L-glutamine 
(200 raM), and 2-mercaptoethanol (5 x  10  -s M). 
Preparation of Antigen-reactive T Cell Lines.  A  continuously growing OVA-reactive T 
cell line was produced and maintained according to the procedure of Kimoto and Fathman 
(19). Briefly, BALB/c mice were immunized in the footpad with 100 t*g OVA emulsified 
in complete Freund's adjuvant (Difco Laboratories Inc.,  Detroit, MI).  Draining lymph 
nodes were removed 7 d later, T  cells were purified by passage over nylon wool columns 
(24), and then cultured in medium containing OVA  I00 t*g/ml and -v-irradiated (3,300 
R) syngeneic spleen cells as a source of antigen-presenting cells (APC). A long-term T cell 
line was established from this initial culture by serial restimulation of Ficoll-recovered T 
blasts (10"~/ml) with either "v-irradiated spleen cells (5  x  106/ml)  alone, or -v-irradiated 
spleen cells plus antigen (100 t*g/ml). This line has been maintained in vitro without loss 
of antigen specificity for more than  18 too. The proliferative response of the line was 
periodically assayed by culturing 104 Ficoll-purified T  cells together with  10  ~ irradiated 
(3,300  R)  syngeneic spleen cells  with or without OVA (100t*g/ml) in microtiter wells 
(Costar 3596) for 2.5 days, followed by a 16-h pulse with [3H]thymidine. 
Several other antigen-reactive T  cell lines were also developed as previously described 
(25). Clones from these lines were derived by limiting dilution, plating the cells at an 
initial average density of 0.3 cells/well. The antigen specificities and genetic haplotypes 
of these lines were as follows: A3 is a B10.A-derived pigeon cytochrome c-specific T  cell 
line; A2.9 is a B10.A pigeon cytochrome c-specific T  cell clone; and 9R.1 is a B10.S(9R)- 
derived pigeon cytochrome c-specific T cell clone. 
BCGF-I Assay.  Full details of this co-stimulator assay are given elsewhere (13). Briefly, 
splenic B cells were purified by the procedure of Leibson eta]. (9), then cultured at a 
density of 5  x  104 per 200 t*l medium in  flat bottom 96-well microtiter plates.  Some 
cultures contained affinity-purified goat anti-t* antibodies at 5-10 t*g/ml final concentra- 
tion and/or dilutions of the various growth factor preparations. Cultures were incubated 
at 37 °C in a humidified atmosphere of air containing 7.5% CO2 for 3 d. The proliferative 2026  MECHANISM  OF  BCGF-I  PRODUCTION 
response of these cultures was determined by adding [~H]thymidine for the last 16 h of 
culture and measuring 3H-TdR incorporation. A  relative unit of BCGF-I activity was 
defined as the amount of material required to produce 50% of the proliferation caused 
by a saturating amount of EL4 supernatant. Thus, the inverse of  the dilution that produced 
50% of the proliferation obtained with a saturating level of EL4 supernatant defined the 
number of relative units per milliliter (U/ml). 
Biochemical Characterization of B Cell Growth Activity.  The B cell co-stimulating activity 
in antigen-stimulated supernatants from the continuously growing OVA-reactive T  cell 
was  characterized  biochemicaily by phenyl Sepharose  chromatography and  IEF.  Full 
details of these procedures are given elsewhere (22, 23). 
Lyt Phenotype Analysis.  The Lyt phenotype of BCGF-I producing T  cells was assessed 
by selective cytotoxicity. Long-term OVA-reactive T cell blasts were recovered on Ficoll 
gradients following a 2-wk antigen-rest period, washed twice, then incubated at 2 ×  105/ 
ml with either the rat anti-mouse Lyt-1 hybridoma (clone 53-7.3) and/or rat anti-mouse 
Lyt-2 hybridoma (clone 53-6.7) at final concentrations of 1:10. As these IgG2a monoclonal 
antibodies are not directly cytotoxic, it was essential to include the complement-binding 
monoclonal mouse anti-rat kappa antibody (MAR 18.5) to this cocktail in order to form 
a cytotoxic sandwich. The anti-Lyt and anti-kappa reagents were produced and generously 
provided by J. Ledbetter and L. Lanier, respectively (26,  27).  Following incubation for 
30  rain  at  4°C,  the  cells  were  washed,  incubated  for  45  min  at  37°C  with  rabbit 
complement at  1:15  (Cedarlane, Low-tox), then washed twice in culture medium. To 
ensure comparison of equivalent precytotoxicity numbers of T  cells, the entire contents 
of both control and test samples  were then placed into a  microtiter well in 200 t~l of 
culture medium containing 5 ×  10  ~ ~,-irradiated syngeneic spleen cells and OVA (100 ~g/ 
ml). Supernatants were collected 24 h later and assayed for BCGF-I production. 
Anti-IL-2 Receptor Antibody (a7D4).  A  monoclonal rat anti-mouse IL-2 receptor anti- 
body was produced by immunization of rats with the IL-2-dependent T  cell line HT2. 
Full details of this antibody and its speciticity for the IL-2 receptor are presented elsewhere 
(28).  Briefly, this reagent reacts with a  membrane antigen of 50,000-60,000  daltons 
expressed on activated but not resting lymphocytes (28), immunoprecipitates cell associ- 
ated IL-2 (28), and blocks proliferation of IL-2-dependent HT2 and CTLL cells (28), but 
not the proliferation of LPS or anti-Ig activated B cells  (T.  Malek and  M.  Howard, 
unpublished observations). 
Results 
BCGF-I Activity in Antigen-stimulated  T  Cell Line Supernatants.  OVA-primed T 
cells were grown in continuous cell culture according to the procedure of Kimoto 
and Fathman (19). Activation of this line to proliferate required specific antigen 
presented  in  the  context  of  syngeneic  irradiated  spleen  cells.  Supernatants 
collected 4 d after stimulating the T  cell line with OVA plus irradiated syngeneic 
spleen cells were tested for BCGF-I activity using the B cell co-stimulator assay 
developed previously (13). Such supernatants (Tova sup) did not directly induce 
proliferation of purified B  lymphocytes, but were  capable of synergizing with 
anti-Ig antibodies to  induce proliferation  levels comparable  to  those achieved 
with induced EL4 supernatants (Fig.  1).  The activity of Tova sup was not H-2 
restricted, as BALB/c, CBA/J, and B10.A B cells all responded in comparable 
fashion to the  BALB/c T  cell  line product  (Figs.  1 and  2).  B  cells from mice 
bearing the xid-determined immune defect (i.e. CBA/N mice) failed to prolifer- 
ate in the presence of anti-Ig plus Tova sup (Fig.  1). By these functional criteria 
TovA sup could not be distinguished from PMA-induced EL4 sup (Figs.  1 and 
2).  Indeed, no synergistic or additive proliferation levels were  obtained  when 
anti-Ig activated B cells were cultured with Tova sup supplemented with optimum BALB/c B CELLS 
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FIGURE  1.  Proliferative response of purified B cells from different strains of mice to anti- 
IgM antibodies plus various dilutions of either a  2-d PMA-induced EL4 supernatant or a 4-d 
OVA-induced long-term T  cell line supernatant. All groups represent the mean of duplicate 
cultures incubated for 3 d, with proliferation assessed via a final 16-h pulse of [~H]thymidine. 
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FIGURE 2.  Proliferative response of purified B10.A B cells cultured with (0 •  i) or without 
(O [] A) anti-IgM antibodies and various dilutions of either 4-d OVA-induced long-term T  cell 
line  supernatant  (left)  or  2-d  PMA-induced  EL4  supernatant (right).  Some  cultures  were 
additionally supplemented with 5% (• Pl) or 10% (A A) of either the EL4 supernatant (left)  or 
the T  cell line supernatant (right).  Other details as in Fig.  1. 
amounts of EL4 sup, or vice versa (Fig. 2). 
The above  data strongly  suggest  that B  cell co-stimulating activities  in Tova 
sup and EL4 are identical.  To confirm this, the active  component of Tova sup 
was characterized  by IEF and phenyl  Sepharose  chromatography  and its prop- 
erties compared to those previously reported (22, 23) for BCGF-I obtained from 
EL4 cells. The B cell co-stimulating factor in Tova sup had isoelectric points for 
6.4  and  7.4  (Fig.  3)  and  on  phenyl  Sepharose  hydrophobic  chromatography 
eluted in the  10-30%  ethanediol fraction (Fig. 4). Thus, by both procedures,  it 
was indistinguishable from the BCGF-I in induced EL4 sup (22, 23). From these 
biologicaI  and biochemical  data we therefore  conclude  that antigen-stimulated 2028  MECHANISM  OF  BCGF-I  PRODUCTION 
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FIGURE 3.  Isoelectric focusing analysis of B cell co-stimulator activity in 4-d OVA-induced 
long-term T  cell line supernatant.  Fractions collected after isoelectric focusing were dialyzed 
extensively, then added at six serial dilutions to duplicate cultures of purified B cells and anti- 
IgM for assay of co-stimulator activity. Proliferation was assessed at day 3, with units of activity 
calculated as described in the Materials and Methods. 
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FIGURE 4.  Phenyl Sepharose chromatographic analysis of B cell co-stimulator activity in 4-d 
OVA-induced long term T cell line supernatant. Fractions were assayed for B cell co-stimulator 
activity as described in Fig. 3 legend. Fractions were assayed for IL-2 activity via proliferation 
of the I L-2-dependent T  cell clone, HT2, as described elsewhere (I 3). 
T  cell lines produce BCGF-I. Interestingly, TOVA supernatant collected 4 d after 
antigenic stimulation ws found to lack the T  cell proliferation cofactor IL-2 (Fig. 
4; unpublished observations), thus further distinguishing these two lymphokines 
and providing a convenient IL-2-free source of BCGF-I. HOWARD ET  AL.  2029 
Characteristics of BCGF-I Production  by Antigen-stimulated  T Cell Lines.  To inves- 
tigate the kinetics of BCGF-I production by antigen-activated T  cell lines, OVA- 
reactive  T  cells  were  collected after  they had  been  cultured  for  2  wk  in  the 
presence of APC but in the absence of  antigen. Such "rested" cells were stimulated 
with OVA plus irradiated syngeneic spleen cells, and cell-free supernatants were 
collected  1,  2,  3,  4, and 5  d  thereafter. Excellent BCGF-I activity was detected 
in  each  supernatant,  with  essentially no  quantitative  difference betweeen  the 
different time points (Fig. 5).  The amount of BCGF-I produced within 24 h  of 
stimulating  105  OVA-reactive  T  cells was comparable  to that produced by 20 
times as many EL4 cells stimulated for 48 h  with phorbol myristate acetate (Fig. 
5). No BCGF-I was detected in supernatants collected from cultures of irradiated 
syngeneic spleen  plus  OVA  (Fig.  5).  Small but detectable amounts of BCGF-I 
were  found in  supernatants  from antigen-free cultures  containing T  cell  plus 
irradiated  syngeneic spleen  cells  (Fig.  5).  As  some proliferation  was also  seen 
under these latter conditions, this production might reflect either a small degree 
of antigen carry-over or a  small degree of autologous MLR activity by cells in 
this line.  No  BCGF-I  activity was found in  supernatants collected from OVA- 
reactive T  cells stimulated with antigen presented  in the context of irradiated 
allogeneic spleen cells (data not shown), demonstrating that induction of BCGF- 
I  production  is  H-2  restricted.  Treatment  of the  OVA-reactive  T  cells  with 
cytotoxic anti-Lyt reagents before antigenic stimulation revealed that the cells in 
this line which are involved in BCGF-I production bear the Lyt 1  +2- phenotype 
(Fig.  6).  As  few  Lyt 2 + T  cells are  propagated  by this method of continuous 
FIGURE 5.  Kinetics  of BCGF-I production by antigen-stimulated  T cells. Cultures containing 
various combinations of 10  "~ Ficoll-purified  long-term OVA reactive T cells collected at the 
end of a 2-wk  antigen rest period, 5 x 106 irradiated (3,300 rads) syngeneic  spleen cells  (APC), 
and OVA at 100 #g/ml were incubated for 1, 2, 3, 4, or 5 d. Supernatants collected  thereafter 
were assayed  for BCGF-I activity via their addition at various dilutions to cultures of purified 
B cells and anti-IgM. The range of proliferative responses  observed in control cultures lacking 
anti-IgM is shown by the hatched regions of the figure. All groups represent duplicate  cultures. 2030  MECHANISM  OF  BCGF-I  PRODUCTION 
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FIGURE 6.  Lyt phenotype of BCGF-I producing cells in the OVA-reactive long term T  cell 
line. T  cells were treated with cytotoxic monoclonal anti-Lyt reagents plus complement before 
their stimulation with OVA and irradiated spleen cells.  Supernatants collected 2 d later were 
assayed for BCGF-I activity as described in Fig. 5. All groups represent duplicate cultures. 
antigen-induced T  cell cultivation, it should not, however be concluded that Lyt 
2 + T  cells fail to produce BCGF-I. Finally, the relationship betwen T  cell density 
and BCGF-I production (Fig.  7) was found to be nonlinear  and showed that as 
few as 104 OVA-reactive T  cells produced detectable levels of BCGF-I within 24 
h of stimulation with antigen plus irradiated syngeneic spleen cells. 
IL-2  Induces  BCGF-I  Production  by  T  Cell  Lines.  Current  models  of T  cell 
activation  propose  that  antigen  presented  in  the  context  of syngeneic  APC 
induces  resting  T  cells  to  express  IL-2  receptors,  and  that  IL-2  causes  these 
activated lymphocytes to proliferate  (29).  The above experiments demonstrate 
that in the case of Lyt 1  + T  cells at least, this activation process is accompanied 
by induction  of BCGF-I release.  To test whether  the stimulus for lymphokine 
release is also provided by IL-2, OVA-specific T  cells were collected at the end 
of a  2-wk antigen  rest period and stimulated with purified BCGF-I-free prepa- 
rations of IL2. Cell-free supernatants collected 2 d later were assayed for BCGF- 
I activity. Both phenyl Sepharose-purified IL-2 from PMA-induced EL4 super- 
natant  and  affinity-purified  human  IL-2  induced  105  OVA-specific T  cells to 
produce substantial amounts of BCGF-I (Table I). Similar results were obtained 
using IEF purified IL-2 from PMA-induced EL4 supernatant  (data not shown). 
In  all  experiments  of this  type,  the  level of IL-2-induced  BCGF-I  production 
corresponded  to  between  10  and  20%  of that  achieved  when  T  cells  were HOWARD  ET  AL.  2031 
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FIGURE 7.  Relationship between T  cell density and BCGF-I production.  Various numbers 
of OVA-reactive T  cells collected at the end of a  2-wk antigen rest period were stimulated 
with OVA and irradiated spleen. Supernatants  collected 1 d  later were assayed for BCGF-I 
activity as described in Fig. 5. All groups represent duplicate cultures. 
stimulated  with  antigen  in  the  context  of  syngeneic  spleen  cells  (Table  I). 
Titration of the amount of IL-2 required for BCGF-I production showed that as 
little  as  10  U/ml  IL-2  induced  105  T  cells  to produce optimum amounts of 
BCGF-I (Fig. 8). This production was totally blocked by a monoclonal rat anti- 
mouse IL-2 receptor antibody (designated a7D4) but not by a  monoclonal rat 
anti-mouse Lyt-1 antibody (Fig. 8). As the anti-IL-2 receptor antibody by itself 
showed no intrinsic blocking effects in the BCGF-I  assay (M.  Howard and T. 
Malek,  unpublished data),  these data  indicate  that  BCGF-I  production in the 
above experiments had indeed resulted  from a  direct effect of IL-2  at the T 
cell's  IL-2  receptor.  While abrogation  of IL-2-induced BCGF-I production in 
the above antibody-blocking experiments was accompanied by elimination of the 
T  cell proliferative response (Table II), separate experiments showed that non- 
proliferating irradiated T  cells were capable of producing optimum amounts of 2032  MECHANISM  OF  BCGF-I  PRODUCTION 
TABLE  I 
Production of BCGF-I by an OVA-Specific  T Cell Line in Response  to Various  Stimuli 
BCGF-I 
Stimulus  Exp.  1"  Exp. 2* 
+ T cells  -  T cells  + T cells  -  T cells 
U/ml 
0  4  <2  3  <2 
Mouse IL-2*  96  <2  272  <2 
Human IL-20  96  <2  256  <2 
OVA-irradiated spleen  !  1024  <2  1792  <2 
* 105 antigen-rested T cells were cultured with various stimuli for 2 d; supernatants were harvested 
and assayed for BCGF-I. Parallel cultures lacking T cells were included to control for any BCGF-I 
derived from the stimulant. 
~; Mouse  IL-2 =  phenyl Sepharose-purified IL-2 from  PMA-induced EL4 supernatant added to 
cultures at ~ 10 U/ml. 
0 Human IL-2 -- affinity-purified IL-2 from induced Jurkat supernatant, provided by Dr. K. Smith, 
added to cultures at ~25 U/ml. 
!  Syngeneic spleen cells were cultured with OVA 100 #g/ml for 3 h,  washed,  irradiated at 3,300 
fads, and added to cultures at 5 x  106/ml. 
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FIGURE 8.  BCGF-I production by long-term OVA-reactive T  cells stimulated for 2 d with 
various concentrations of phenyl Sepharose-purified murine IL-2. Some cultures also con- 
tained either anti-Lyt-I hybridoma supernatant or a7D4  (anti-IL-2 receptor) hybridoma 
supernatant added at final concentrations of 1  : 10. Control experiments showed that 56 U/ml 
of the  partially purified IL-2 contained <2  U/ml  BCGF-I activity. All groups  represent 
duplicate cultures. 
BCGF-I  in  response  to  either  IL-2  or  antigen-pulsed  APC  (Table  III).  Thus, 
while proliferation and lymphokine release are apparently mediated via the same 
receptor-ligand  interactions,  they  are  nevertheless  independent  events.  The 
results of Table III also demonstrate  that Con A, particularly when presented in 
the context of syngeneic irradiated spleen, is capable of inducing antigen-reactive 
T  cells to secrete BCGF-I. While this observation is readily explained by Con A- 
inducing T  cells to secrete IL-2 which in turn  induces BCGF-I production,  it is 
nevertheless intriguing in light of the apparent  difficulty of detecting BCGF-I in 
Con A-induced  spleen cell supernatants (M. Howard,  unpublished observations). HOWARD  ET  AL.  2033 
TABLE  II 
Effect of Anti-IL-2 Receptor Antibody (a7D4) on Antigen or IL-2 Induction of an OVA-reactive T 
Cell Line 
Stimulus*  BCGF-I Production  Proliferation 
U/ml  cpm 
0  4  893 
IL2  256  9,809 
IL2 +  a7D4  12  603 
IL2 +  aLytl  228  8,695 
OVA-irradiated spleen  1,792  39,291 
OVA-irradiated spleen +  a7D4  1,536  29,292 
OVA-irradiated spleen +  aLyt 1  2,048  31,685 
*  10  ~ antigen-rested T  cells were  cultured  with  the  various stimuli  listed.  Induction  of BCGF-I 
production was assessed by assaying the amount of BCGF-I in supernatants collected 2  d  later. 
Induction of proliferation was assessed via the uptake of ~H-TdR on day 3. For details of the mouse 
IL-2 and OVA pulsed irradiated spleen cell stimulants, refer to Table I. For details of the a7D4 
and aLytl antibodies, refer legend to Fig. 8. 
TABLE  III 
BCGF-I Production by and Proliferation of Nonirradiated and Irradiated T Cells  following 
Stimulation 
Stimulus 
BCGF-I Production*  Proliferation* 
No T  cells  Normal T  Irradiated  Normal T  Irradiated 
ceils  T  cells  0  cells  T  cells  j 
U/ml  cpm 
+0  <2  <2  <2  2,100  450 
+IL2 i  <2  96  72  16,670  363 
+Irradiated spleen & OVA  <2  512  512  33,019  450 
+Con A ~  <2  320  ND  5,099  ND 
+Con A +  irradiated spleen  <2  960  ND  75,842  ND 
* BCGF-I production estimated as in Table I. 
* Proliferative response estimated by culturing 2 X 104 OVA reactive T cells per microtiter well plus 
the various stimuli for 3 d with a final 16-h pulse of [3H]thymidine. 
Irradiated T  cells received 3,300 rads before culture. 
!  See footnote at of Table I. 
Con A was used at 1 #g/ml. 
Interestingly,  the anti-IL-2  receptor antibody used in  the above experiments 
failed to abrogate either BCGF-I production or proliferation ofT cells stimulated 
with  antigen  and  syngeneic  APC  (Table  II).  Possible  explanations  for  this 
observation are discussed below. 
Finally, to test the generality of the above findings, the same BCGF-I induction 
experiments were performed using other antigen-reactive  T  cell  lines.  Three 
long-term  lines, two of which had  additionally been  cloned by  limit dilution, 
were used for this purpose. Two of these three lines produced BCGF-I in response 
to specific antigen presented in the context of syngeneic spleen cells (Table IV); 
all three of the lines produced BCGF-I in response to phenyl Sepharose-purified 
IL-2 (Table IV). In contrast to the above situation with the OVA-reactive T  cell 
line, IL-2 proved equal to or better than presented antigen in inducing BCGF-I 2034  MECHANISM  OF  BCGF-I  PRODUCTION 
TABLE  IV 
BCGF-I Production  by Other Antigen-reactive  T Cell Lines 
T  cell line  * 
BCGF-1 
+  lrra-  +  Irra- 
diated  diated  +  IL.2 ! 
spleen  spleen + 
antigen 
U/ml 
A2.9  4  48  32 
9R. 1  <2  24  64 
A3  <2  <2  48 
* Conditions for BCGF-I production as in Table 1. 
*  For details on antigen specificity and genetic haplotype of T  cell lines, 
see Materials and Methods. 
!  IL-2  -- phenyl Sepharose-purified mouse  IL-2, added at  ~10  U/ml. 
This mixture contained <2  U/ml BCGF-I. 
production by these T  cell lines (Table IV). As cloning of T  cell lines involves 
an  initial  IL-2-dependent propagation  step,  this  may simply reflect selection 
during cloning of T  cells that are highly IL-2-responsive. 
From these data we conclude that BCGF-! production is a common feature of 
long-term antigen-reactive T  cell lines when stimulated either with presented 
antigen or IL-2. 
Discussion 
This study demonstrates the production of murine BCGF-I by antigen-reactive 
long-term T  cell lines and T  cell clones following stimulation with either antigen 
presented in the context of syngeneic spleen cells, or alternatively IL-2. While 
BCGF-I has been found in supernatants of T  cell hybridomas, lymphomas, and 
alloreactive  T  cell  clones  (13,  30-32),  this  is  the  first  demonstration  of its 
production by normal mouse T  cells in response to antigenic stimulus. As most 
other sources of BCGF-I require induction by PMA or Con A, the current source 
provides  the added  advantage  of being  mitogen-free. The  fact  that  BCGF-I 
production by the OVA-reactive T  cell line used throughout most of this study 
was substantially greater using presented antigen as the inductant rather than 
IL-2 can be readily explained by a consideration of the physiology of this type 
of T  cell line. The optimum procedure for growing such lines on alternate cycles 
of antigen-rest and antigen-exposure is consistent with the fact that T  cells lose 
their IL-2 receptors some time after activation (29). Thus, at the end of a  2-wk 
antigen-rest period the T  cell lines will most likely comprise a mixture of IL-2- 
receptor-bearing  cells  and  cells  that  have  already  lost  their  IL-2  receptors. 
Whereas  IL-2  induction  will  only  encompass  the  first  of these  populations, 
antigen plus APC has the potential to recruit both i.e., to re-activate expression 
of IL-2-receptors and to generate IL-2 to act on such receptors. In contrast, the 
antigen-reactive  T  cell  clones  analysed  for  BCGF-I  production  showed  the 
reverse preference for IL-2 rather than presented antigen as optimum inductant. 
As mentioned above, this may reflect selection for enhanced IL-2 responsiveness 
during the cloning procedure. 
Our observation that antibodies to the IL-2 receptor block BCGF-I production HOWARD ET AL.  2035 
in response to IL-2 but not in response to presented antigen, raises the possibiity 
that a mechanism independent of engagement of the IL-2 receptor can be used 
to  cause  BCGF-I  production.  Since  [3H]thymidine  uptake  by  these  cells  in 
response to antigen and APC is also not blocked by the anti-receptor antibody, 
this  would further imply that an  IL-2-independent mechanism may exist for 
proliferation of these T  cells. Such a  conclusion, however appears to us to be 
premature. The results might equally well be explained by the induction on T 
cells of large numbers of IL-2 receptors as a result of stimulation by antigen and 
APC,  making such cells much more difficult to block than cells simply treated 
with  IL-2.  Alternatively,  antigenic  stimulation  might  induce  the  T  cells  to 
produce  IL-2  and  IL-2  receptors simultaneously.  Under these  circumstances 
receptor-ligand complexes could be formed intracytoplasmically, i.e. before their 
surface expression, thereby removing all opportunity for an extracellular anti- 
body to  compete in  the  interaction.  Thus,  antigen-induced proliferation  and 
BCGF-I production by T cells may also be mediated by the IL-2 receptor, despite 
the fact that both processes are refractory to the blocking effects of the anti-IL- 
2 receptor antibody. 
This paper contributes to our growing knowledge of the lymphokine cascade 
that  apparently  regulates  the  effector mechanisms of the  immune response. 
Others have shown that T  cell-derived colony-stimulating-factor induces mac- 
rophages to release IL-1, which in turn stimulates T cells to release IL-2 (reviewed 
in reference 22). Here we demonstrate that IL-2 in turn acts on T  cells to release 
the B cell proliferation cofactor BCGF-I. Thus, IL-2 is a bifunctional mediator 
capable of inducing T  cells to proliferate and/or secrete BCGF-I.  Such pluri- 
function has previously been reported in the case of the biochemically similar 
lymphokine colony stimulating  factor,  a  mediator  that  acts  on  macrophages, 
inducing both proliferation (33) and effector cell function (34, 35). Whether all 
B cell-specific cofactors are induced by IL-2 is not yet clear. Antigen stimulation 
of long-term T  cell lines similar to those used in  this study is known to cause 
release of other B ceil-specific cofactors (36-38), but the mechanisms governing 
those events have not yet been elucidated. Preliminary evidence from Swain and 
colleagues suggests that IL-2 induces an allorective T  cell line to produce B cell 
differentiation factors and the second B cell growth factor BCGF-II (reference 
39; S. Swain, personal communication). In contrast however, Asano et al. (40) 
have demonstrated that antigen-reactive T  cell clones are capable of providing 
helper T  cell function in an antibody response at antigen concentrations below 
which proliferation and thus, presumably IL-2 release are observed. Whether or 
not  IL-2  induces all  B  cell-specific cofactors,  one  should  not  regard  it  as  a 
universal lymphokine inductant. At least in the case of interferon, lymphokine 
production by antigen-reactive T  cell clones has been segregated from prolifer- 
ation and IL-2 induction (41).  The fact that IL-2 causes production of at least 
some  B  cell-specific  interleukins  may  well  explain  the  current  controversy 
regarding the role of IL-2 in B cell immunity (reviewed in reference 18).  The 
current studies demonstrate that as few as 104 T cells produce detectable amounts 
of BCGF-I. While proponents of IL-2 acting directly on B cells may feel confident 
that their starting B cell population is free of this level of T  cell contamination, 
an even lower level may well expand to such a number in the presence of IL-2 2036  MECHANISM  OF  BCGF-I  PRODUCTION 
during the 3-5-d culture periods generally used. 
The demonstration of BCGF-I production by antigen-reactive MHC-restricted 
helper T  cells prompts some modification of current models that divide B cell 
triggering into either factor-mediated or involving cognate T  cell interactions 
(discussed in reference 18). In light of the present study, cognate T  cell interac- 
tions will presumably generate at least some B cell-specific interleukins. Thus it 
seems more likely that both pathways will use similar, if not the same, cofactors. 
The  apparent  difference between  those  B  cells  that  appear  to  utilize  direct 
interactions with T  cells for their activation and those B cells that do not could 
be explained at the level of cofactor receptor expression, i.e.,  that the role of 
cognate T  cell interaction may be to induce a membrane receptor for a B cell- 
specific interleukin; other B cells may already express this receptor or develop it 
in response to membrane immunoglobulin cross-linkage by antigen, thus bypass- 
ing  the  need  for  a  cognate  T  cell  signal.  Testing  of this  model  and  direct 
demonstration that the cognate interaction pathway utilizes factors will hopefully 
be possible when antibodies against the factors or their membrane-bound recep- 
tors are developed. 
Summary 
Antigen-activated T  iymphocytes produce within 24 h of stimulation a factor 
that  is  indistinguishable  biochemically and  functionally from  the  B  cell  co- 
stimulating growth factor, BCGF-I, originally identified in induced EL4 super- 
natants:  Supernatants  from  antigen-stimulated  T  cell  lines  are  not  directly 
mitogenic for resting B cells, but synergize in an H-2-unrestricted manner with 
anti-Ig activated B cells to produce polyclonal proliferation but not antibody- 
forming-cell development; biochemical studies reveal the B cell co-stimulating 
factor present in antigen-stimulated T cell line supernatants is identical by phenyl 
Sepharose chromatography and isoelectric focusing (IEF) to  EL4  supernatant 
BCGF-I. We thus conclude that normal T  cells produce BCGF-I in response to 
antigenic stimulation. 
Analysis of the mechanism of BCGF-I production by antigen-stimulated T cells 
showed that optimum amounts of BCGF-I were obtained as quickly as 24 h post- 
stimulation, and that the factor producing cells in  the T  cell line investigated 
bore the Lyt-l+2  - phenotype. As few as 104 T  cells produced sufficient BCGF-I 
to support the proliferation of 5 ×  104 purified anti-Ig activated B cells. Finally, 
the activation of normal T  cell lines to produce BCGF-I required either antigen 
presented in the context of syngeneic antigen-presenting cells (APC) or interleu- 
kin 2 (IL-2). 
Note added in proof'. After this paper was submitted, a working group on B cell 
factors  met  in  Kyoto  and  proposed  that  BCGF-I  be  designated  BSF  (B  cell 
stimulatory factor). 
We thank Dr. Kendall Smith for providing us with affinity-purified human IL-2. HOWARD  ET  AL.  2037 
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